Pulmatrix Shifts Focus Following Termination of Merger with Cullgen

Framingham, Mass. (March 2, 2026) – In a recent announcement, Pulmatrix, Inc., a notable biopharmaceutical company known for its innovative inhaled therapeutic products, stated that it will continue exploring alternative merger opportunities after the abrupt termination of its planned merger with Cullgen Inc. This decision comes on the heels of lengthy delays caused by regulatory processes at the Chinese Securities Regulatory Commission (CSRC), which ultimately derailed the collaboration.

Background of the Termination

On February 28, 2026, Cullgen officially notified Pulmatrix of its decision to terminate the merger agreement, which had been established to combine their resources and expertise in the development of advanced therapeutics. This development follows an earlier mutual agreement in December 2025 that allowed both companies to seek other potential transactions while they continued discussions regarding the merger. Peter Ludlum, the interim CEO of Pulmatrix, expressed disappointment yet optimism regarding the company’s future. He noted that, despite the challenges faced, there has been significant interest in potential partnership opportunities, alongside an uptick in transaction activity within the biopharmaceutical sector.

The iSPERSE™ Technology Advantage

Pulmatrix has been at the forefront of developing cutting-edge inhalation technologies aimed at addressing critical health issues, particularly those related to migraine and respiratory diseases. Their proprietary iSPERSE™ technology enables more effective delivery of therapeutic agents, promising better distribution and uptake in the lungs compared to conventional methods. As of late 2025, Pulmatrix's patent portfolio boasted around 149 granted patents with additional filings pending, indicating a robust pipeline equipped to tackle various unmet medical needs.

Clinical Assets and Future Prospects

Among its promising candidates is PUR3100, which is being developed as a treatment for acute migraines and has recently received Investigational New Drug (IND) application acceptance from the FDA. Building on the encouraging outcomes from its Phase 1 trials, the company is gearing up for a Phase 2 clinical study to further investigate its efficacy and safety.

In addition to PUR3100, Pulmatrix is advancing its asset PUR1800, aimed at treating acute exacerbations in chronic obstructive pulmonary disease (COPD). Early studies have shown it to be well-tolerated, supporting ongoing development. Furthermore, PUR1900, an inhaled formulation of the antifungal drug itraconazole, is progressing to Phase 3 trials in India, driven by clinical insights from previous studies and collaborations with partners like Cipla.

Challenges and Strategic Adjustments

The termination of the merger has prompted Pulmatrix to reassess its strategic direction, particularly in pursuing new partnerships that align with its innovative therapeutic goals. The biopharmaceutical landscape remains competitive, and while Pulmatrix faces challenges related to funding and regulatory approvals, its strong patent portfolio coupled with advancing clinical trials positions it favorably within the industry.

As the company transitions away from its previous merger plans, stakeholders will be keenly watching its maneuvers to secure alternative partnerships that can bolster its mission of mitigating unmet medical needs through effective therapeutics. Continued advancements in their clinical pipelines and strategic alliances will remain essential components of Pulmatrix's roadmap as it navigates the evolving regulatory and business landscapes.

Conclusion

Pulmatrix’s determination to forge a new path following the merger termination underscores its commitment to innovation and addressing critical healthcare challenges. With the support of its pioneering iSPERSE™ technology and a dynamic portfolio of clinical assets, the company is poised to make a meaningful impact in the realm of biopharmaceuticals, even amidst the current setbacks. As they pursue new merger opportunities, the healthcare community will be closely observing Pulmatrix’s next steps.